stockrowZymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) Total debt
Zymeworks Inc.'s total debt at the end of fiscal 2022 was $24.8M, down 20.1% from $31.0M in fiscal 2021. At the end of the quarter to 31 March 2026 it was $278.0K. Over the past ten years it has ranged from $42.0K (fiscal 2018) to $31.0M (fiscal 2021); the current reading is higher than 86% of that period. Zymeworks Inc. ranks 456th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $24.8M | (20.09%) |
| FY2021 | $31.0M | 422.80% |
| FY2020 | $5.9M | 5.12% |
| FY2019 | $5.6M | 13,340.48% |
| FY2018 | $42.0K | (19.23%) |
| FY2017 | $52.0K | (98.82%) |
| FY2016 | $4.4M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Mar 2026 | $278.0K | 0.00% |
| Dec 2025 | $278.0K | (98.77%) |
| Sep 2023 | $22.5M | (4.58%) |
| Jun 2023 | $23.6M | (1.49%) |
| 19 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BHVN Biohaven Ltd. compare | $264.3M |
| VCEL Vericel Corporation compare | $85.1M |
| VERA Vera Therapeutics, Inc. compare | $75.2M |
| AUPH Aurinia Pharmaceuticals Inc compare | $39.0M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $5.5M |
| ZYME Zymeworks Inc. | $278.0K |
| IMNM Immunome, Inc. compare | $228.0K |
| COAG Hemab Therapeutics Holdings, Inc. compare | — |
| SEPN Septerna, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ZYME
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement